Search

Your search keyword '"Takigawa, Nagio"' showing total 1,028 results
Start Over Author "Takigawa, Nagio"
1,028 results on '"Takigawa, Nagio"'

5. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study

Author

Kuribayashi, Tadahiro, Ohashi, Kadoaki, Nishii, Kazuya, Ninomiya, Kiichiro, Tsubata, Yukari, Ishikawa, Nobuhisa, Kodani, Masahiro, Kanaji, Nobuhiro, Yamasaki, Masahiro, Fujitaka, Kazunori, Kuyama, Shoichi, Takigawa, Nagio, Fujimoto, Nobukazu, Kubota, Tetsuya, Inoue, Masaaki, Fujiwara, Keiichi, Harita, Shingo, Takata, Ichiro, Takada, Kenji, Okawa, Sachi, Kiura, Katsuyuki, and Hotta, Katsuyuki

Published
2024
Full Text
View/download PDF

11. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

Author

Ogura, Takashi, Takigawa, Nagio, Tomii, Keisuke, Kishi, Kazuma, Inoue, Yoshikazu, Ichihara, Eiki, Homma, Sakae, Takahashi, Kazuhisa, Akamatsu, Hiroaki, Ikeda, Satoshi, Inase, Naohiko, Iwasawa, Tae, Ohe, Yuichiro, Ohta, Hiromitsu, Onishi, Hiroshi, Okamoto, Isamu, Ogawa, Kazumasa, Kasahara, Kazuo, Karata, Hiroki, Kishimoto, Takumi, Kitamura, Yuka, Gemma, Akihiko, Kenmotsu, Hirotsugu, Sakashita, Hiroyuki, Sakamoto, Susumu, Sekine, Katsutoshi, Takiguchi, Yuichi, Tada, Yuji, Toyooka, Shinichi, Nakayama, Yuko, Nishioka, Yasuhiko, Hagiwara, Koichi, Hanibuchi, Masaki, Fukuoka, Junya, Minegishi, Yuji, Yanagihara, Toyoshi, Yamamoto, Nobuyuki, Yamamoto, Hiromasa, Gaga, Mina, Fong, Kwun M., Powell, Charles A., and Kiura, Katsuyuki

Published
2019
Full Text
View/download PDF

12. MO35-6 Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)

Author

Morikawa, Kei, primary, Takata, Saori, additional, Tanaka, Hisashi, additional, Horiuchi, Kazuya, additional, Okuma, Yusuke, additional, Soejima, Kenzo, additional, Nakagawa, Hideyuki, additional, Nakahara, Yoshiro, additional, Seki, Yoshitaka, additional, Bessyo, Akihiro, additional, Takahashi, Nobumasa, additional, Hayashi, Kentaro, additional, Endo, Takeo, additional, Takeyama, Ren, additional, Maekura, Toshiya, additional, Takigawa, Nagio, additional, Horimoto, Katsuhisa, additional, Matsutani, Noriyuki, additional, and Seki, Nobuhiko, additional

Published
2023
Full Text
View/download PDF

14. Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: a multicenter, retrospective cohort study.

Author

Miyake, Kohei, primary, Senoo, Satoru, additional, Shiiba, Ritsuya, additional, Itano, Junko, additional, Kimura, Goro, additional, Kawahara, Tatsuyuki, additional, Tamura, Tomoki, additional, Kudo, Kenichiro, additional, Kawamura, Tetsuji, additional, Nakahara, Yasuharu, additional, Higo, Hisao, additional, Himeji, Daisuke, additional, Takigawa, Nagio, additional, and Miyahara, Nobuaki, additional

Published
2023
Full Text
View/download PDF

18. Effect of a Cyclooxygenase-2 Inhibitor in Combination with (−)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice

Author

Sato, Ken, Takigawa, Nagio, Kubo, Toshio, Katayama, Hideki, Kishino, Daizo, Okada, Toshiaki, Hisamoto, Akiko, Mimoto, Junko, Ochi, Nobuaki, Yoshino, Tadashi, Ueoka, Hiroshi, Tanimoto, Mitsune, Maeda, Yoshionobu, and Kiura, Katsuyuki

Subjects
celecoxib, polyphenon E, cisplatin, EGCG, lung tumor
Abstract

We investigated the effects of celecoxib combined with (−)-epigallocatechin-3-gallate (EGCG) or polyphenon E in a cisplatin-induced lung tumorigenesis model. Four-week-old female A/J mice were divided into seven groups: (i) Control, (ii) 150 mg/kg celecoxib (150Cel), (iii) 1,500 mg/kg celecoxib (1500Cel), (iv) EGCG+150 mg/kg celecoxib (EGCG+150Cel), (v) EGCG+1,500 mg/kg celecoxib (EGCG+1500Cel), (vi) polyphenon E+150 mg/kg celecoxib (PolyE+150Cel), and (vii) polyphenon E+1,500 mg/kg celecoxib (PolyE+1500Cel). All mice were administered cisplatin (1.62 mg/kg of body weight, i.p.) 1×/week for 10 weeks and sacrificed at week 30; the numbers of tumors on the lung surface were then determined. The tumor incidence and multiplicity (no. of tumors/mouse, mean±SD) were respectively 95% and 2.15±1.50 in Control, 95% and 2.10±1.29 in 150Cel, 86% and 1.67±1.20 in 1500Cel, 71% and 1.38±1.24 in EGCG+150Cel, 67% and 1.29±1.38 in EGCG+1500Cel, 80% and 1.95±1.36 in PolyE+150Cel, and 65% and 1.05±0.10 in PolyE+1500Cel. The combination of high-dose celecoxib with EGCG or polyphenon E significantly reduced multiplicity in cisplatin-induced lung tumors.

Published
2023

19. Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study.

Author

Miyake, Kohei, Senoo, Satoru, Shiiba, Ritsuya, Itano, Junko, Kimura, Goro, Kawahara, Tatsuyuki, Tamura, Tomoki, Kudo, Kenichiro, Kawamura, Tetsuji, Nakahara, Yasuharu, Higo, Hisao, Himeji, Daisuke, Takigawa, Nagio, and Miyahara, Nobuaki

Subjects
PNEUMOCYSTIS pneumonia, PNEUMONIA-related mortality, STEROID drugs, COHORT analysis, MORTALITY risk factors
Abstract

Objective: Long-term steroid use increases the risk of developing Pneumocystis pneumonia (PcP), but there are limited reports on the relation of long-term steroid and PcP mortality. Methods: Retrospective multicenter study to identify risk factors for PcP mortality, including average steroid dose before the first visit for PcP in non-human immunodeficiency virus (HIV)-PcP patients. We generated receiver operating characteristic (ROC) curves for 90-day all-cause mortality and the mean daily steroid dose per unit body weight in the preceding 10 to 90 days in 10-day increments. Patients were dichotomized by 90-day mortality and propensity score-based stabilized inverse probability of treatment weighting (IPTW) adjusted covariates of age, sex, and underlying disease. Multivariate analysis with logistic regression assessed whether long-term corticosteroid use affected outcome. Results: Of 133 patients with non-HIV-PcP, 37 died within 90 days of initial diagnosis. The area under the ROC curve for 1–40 days was highest, and the optimal cutoff point of median adjunctive corticosteroid dosage was 0.34 mg/kg/day. Past steroid dose, underlying interstitial lung disease and emphysema, lower serum albumin and lower lymphocyte count, higher lactate dehydrogenase, use of therapeutic pentamidine and therapeutic high-dose steroids were all significantly associated with mortality. Underlying autoimmune disease, past immunosuppressant use, and a longer time from onset to start of treatment, were associated lower mortality. Logistic regression analysis after adjusting for age, sex, and underlying disease with IPTW revealed that steroid dose 1–40 days before the first visit for PcP (per 0.1 mg/kg/day increment, odds ratio 1.36 [95% confidence interval = 1.16–1.66], P<0.001), low lymphocyte counts, and high lactate dehydrogenase revel were independent mortality risk factor, while respiratory failure, early steroid, and sulfamethoxazole/trimethoprim for PcP treatment did not. Conclusion: A steroid dose before PcP onset was strongly associated with 90-day mortality in non-HIV-PcP patients, emphasizing the importance of appropriate prophylaxis especially in this population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Supplementary Figure 4 from Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells

Author

Shien, Kazuhiko, primary, Toyooka, Shinichi, primary, Yamamoto, Hiromasa, primary, Soh, Junichi, primary, Jida, Masaru, primary, Thu, Kelsie L., primary, Hashida, Shinsuke, primary, Maki, Yuho, primary, Ichihara, Eiki, primary, Asano, Hiroaki, primary, Tsukuda, Kazunori, primary, Takigawa, Nagio, primary, Kiura, Katsuyuki, primary, Gazdar, Adi F., primary, Lam, Wan L., primary, and Miyoshi, Shinichiro, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 2 from Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells

Author

Shien, Kazuhiko, primary, Toyooka, Shinichi, primary, Yamamoto, Hiromasa, primary, Soh, Junichi, primary, Jida, Masaru, primary, Thu, Kelsie L., primary, Hashida, Shinsuke, primary, Maki, Yuho, primary, Ichihara, Eiki, primary, Asano, Hiroaki, primary, Tsukuda, Kazunori, primary, Takigawa, Nagio, primary, Kiura, Katsuyuki, primary, Gazdar, Adi F., primary, Lam, Wan L., primary, and Miyoshi, Shinichiro, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 2 from Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells

Author

Shien, Kazuhiko, primary, Toyooka, Shinichi, primary, Yamamoto, Hiromasa, primary, Soh, Junichi, primary, Jida, Masaru, primary, Thu, Kelsie L., primary, Hashida, Shinsuke, primary, Maki, Yuho, primary, Ichihara, Eiki, primary, Asano, Hiroaki, primary, Tsukuda, Kazunori, primary, Takigawa, Nagio, primary, Kiura, Katsuyuki, primary, Gazdar, Adi F., primary, Lam, Wan L., primary, and Miyoshi, Shinichiro, primary

Published
2023
Full Text
View/download PDF

47. Data from Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Author

Isozaki, Hideko, primary, Ichihara, Eiki, primary, Takigawa, Nagio, primary, Ohashi, Kadoaki, primary, Ochi, Nobuaki, primary, Yasugi, Masayuki, primary, Ninomiya, Takashi, primary, Yamane, Hiromichi, primary, Hotta, Katsuyuki, primary, Sakai, Katsuya, primary, Matsumoto, Kunio, primary, Hosokawa, Shinobu, primary, Bessho, Akihiro, primary, Sendo, Toshiaki, primary, Tanimoto, Mitsune, primary, and Kiura, Katsuyuki, primary

Published
2023
Full Text
View/download PDF

48. Suppl. Figure 2 from Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Author

Isozaki, Hideko, primary, Ichihara, Eiki, primary, Takigawa, Nagio, primary, Ohashi, Kadoaki, primary, Ochi, Nobuaki, primary, Yasugi, Masayuki, primary, Ninomiya, Takashi, primary, Yamane, Hiromichi, primary, Hotta, Katsuyuki, primary, Sakai, Katsuya, primary, Matsumoto, Kunio, primary, Hosokawa, Shinobu, primary, Bessho, Akihiro, primary, Sendo, Toshiaki, primary, Tanimoto, Mitsune, primary, and Kiura, Katsuyuki, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 3 from Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells

Author

Shien, Kazuhiko, primary, Toyooka, Shinichi, primary, Yamamoto, Hiromasa, primary, Soh, Junichi, primary, Jida, Masaru, primary, Thu, Kelsie L., primary, Hashida, Shinsuke, primary, Maki, Yuho, primary, Ichihara, Eiki, primary, Asano, Hiroaki, primary, Tsukuda, Kazunori, primary, Takigawa, Nagio, primary, Kiura, Katsuyuki, primary, Gazdar, Adi F., primary, Lam, Wan L., primary, and Miyoshi, Shinichiro, primary

Published
2023
Full Text
View/download PDF

50. Suppl. Figure 6 from Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Author

Isozaki, Hideko, primary, Ichihara, Eiki, primary, Takigawa, Nagio, primary, Ohashi, Kadoaki, primary, Ochi, Nobuaki, primary, Yasugi, Masayuki, primary, Ninomiya, Takashi, primary, Yamane, Hiromichi, primary, Hotta, Katsuyuki, primary, Sakai, Katsuya, primary, Matsumoto, Kunio, primary, Hosokawa, Shinobu, primary, Bessho, Akihiro, primary, Sendo, Toshiaki, primary, Tanimoto, Mitsune, primary, and Kiura, Katsuyuki, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results